Trial Profile

A phase 1/2 study of GF 1002 in patients suffering from NASH

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 05 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Feb 2024 According to a Genflow Biosciences PLC media release, company to undertake key Investigational New Drug (IND)-enabling development activities that will help define the pharmacological and toxicological properties of its lead drug candidate, GF-1002, and its potential benefits for NASH patients and initial site selection and QMS framework for clinical readiness, expected by the end of 2025 for the NASH program.
01 Feb 2024 According to a Genflow Biosciences PLC media release, company expects to commence a clinical trial in 2024.
28 Sep 2023 According to a Genflow Biosciences PLC media release, The company's NASH clinical trials are scheduled to begin in approximately 18 months following dialogue and subsequent agreement with the European Medicine Agency.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com